CrushSCI.com
110.1Average days
83Median days
33Fastest days
211Longest days
1852025 publications

Paper Review Records

All Paper Review Records

15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

64 days

Detection of Actionable Genomic Alterations beyond EGFR, ALK and ROS1 in Non-Small Cell Lung Carcinoma: A Real-World Evaluation of a Pathology-Led Staggered Reflex Predictive Biomarker Testing Strategy in a Resource-Limited Setting

Authors
Aruna Nambirajan; Kaustar Yadav; Saumya Sahu; Snehvarsha Bhagat; Prajna Gopalakrishna; Shraddanjali Satapathy; Warisa Khatoon; Suyash Devgan; Amita Singh; Aparna Sharma; Anant Mohan; Prabhat Singh Malik; Chitra Sarkar; Deepali JainShow moreShow less
Affiliations
Department of Pathology, All India Institute of Medical Sciences, New Delhi, India; Department of Medical Oncology, NCI Jhajjar, All India Institute of Medical Sciences, New Delhi, India; Department of Pulmonary and Sleep Medicine, All India Institute of Medical Sciences, New Delhi, India; Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India; Thoracic Pathology Center of Excellence, University of Pittsburgh Medical Center, Pittsburgh, PA, USAShow moreShow less
Source PDF DOI Publisher page
75 days

Real-World Outcomes and Early Progressive Disease Analysis of Nivolumab and Ipilimumab Combination Therapy in Metastatic NSCLC: LIGHT-NING Study 2.5-Year Update

Authors
Hisao Imai; Teppei Yamaguchi; Koichi Azuma; Takashi Kijima; Yukihiro Toi; Kazuma Kishi; Kohei Fujita; Haruhiro Saito; Yoshimasa Shiraishi; Junko Tanizaki; Yuta Takashima; Yuichi Tambo; Satoshi Watanabe; Osamu Hataji; Tatsuro Fukuhara; Tomoyuki Ohsugi; Yu Tobishima; Hidehito HorinouchiShow moreShow less
Affiliations
Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan; Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Division of Respirology, Neurology and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan; Department of Respiratory Medicine and Hematology, Hyogo Medical University, School of Medicine, Nishinomiya, Hyogo, Japan; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Miyagi, Japan; Department of Respiratory Medicine, Toho University Omori Medical Center, Tokyo, Japan; Division of Respiratory Medicine, National Hospital Organization Kyoto Medical Center, Fushimi-ku, Kyoto, Japan; Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Department of Medical Oncology, Kindai University Faculty of Medicine, Sakai, Osaka, Japan; Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan; Department of Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Chuo-ku, Niigata, Japan; Respiratory Center, Saiseikai Matsusaka Municipal Hospital, Matsusaka, Mie, Japan; Department of Respiratory Medicine, Miyagi Cancer Center, Natori, Miyagi, Japan; Oncology Medical, Bristol Myers Squibb, Tokyo, Japan; Oncology Medical Affairs, Ono Pharmaceutical Co., Ltd., Osaka, Japan; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, JapanShow moreShow less
Source PDF DOI Publisher page
138 days

Modified CARG Score-Guided First-Line Treatment in Older or Vulnerable Patients With Advanced Non-Small-Cell Lung Cancer: Results of the Randomized, Phase 2 DURATION Trial (AIO-YMO/TRK-0416)

Authors
Jonas Kuon; Miriam Blasi; FFarastuk Bozorgmehr; Konrad Kokowski; Martin Faehling; Philipp Schütt; Daniel Christoph Christoph; Martin Kimmich; Eva Lotte Buchmeier; Anke Reinacher-Schick; Matthias Ulmer; Christian Meyer zum Büschenfelde; Nicolas Moosmann; Frank Griesinger; Wolfang Schütte; Ludwig Fischer von Weikersthal; Bernd Schmidt; Wolfgang Gleiber; Heinz Kirchen; Martin Wermke; Paul La Rosé; Gerlinde Schmidtke-Schrezenmeier; Jean-Charles Moulin; Michael Boesche; Christian Grohé; Helga Bernhard; Dominik Modest; Christoph Maintz; Marc Alexander Schneider; Rouven Behnisch; Albrecht Stenzinger; Petros Christopoulos; Michael ThomasShow moreShow less
Affiliations
Department of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg TLRC-H, Member of the German Center for Lung Research (DZL), Heidelberg, Germany; Department of Thoracic Oncology, SLK Fachklinik Löwenstein, Löwenstein, Germany; Department for Pneumology and Thoracic oncology, Klinikum Bogenhausen, Bogenhausen, Germany; Department of Cardiology and Pneumology, Hospital Esslingen, Esslingen, Germany; Department Oncological Practice Gütersloh, Gütersloh, Germany; Department of Pneumology and Infectiology, Division of Thoracic Oncology, Thoraxzentrum Evang. Krankenhaus Herne-Eickel, Thoraxzentrum Ruhrgebiet, Herne, Germany; Department of Thoracic Oncology, Robert-Bosch-Hospital Stuttgart, Stuttgart, Germany; Department of Pneumology, Lung Hospital Cologne Merheim, City of Cologne Municipal Hospitals, Cologne, Germany; Lung Clinic Hemer, Department of Pulmonology and Thoracic Oncology, Hemer, Germany; Department of Hematology and Oncology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany; Department of Hematology and Oncolgy, Hospital Ludwigsburg, Ludwigsburg, Germany; Clinic for Hematology, Oncology, Immunology and Palliative Care, St. Vincentius Hospital Karlsruhe, Karlsruhe, Germany; Department of Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg, Germany; Department of Hematology and Oncology, Pius-Hospital, University Medicine Oldenburg University Department Internal Medicine-Oncology, Oldenburg, Germany; Department Internal Medicine II, Hospital Martha-Maria Halle-Dölau, Halle Saale, Germany; Department of Hematology and Oncology, St. Marien Hospital, Amberg, Germany; Department of Pneumology, DRK-Kliniken Berlin Mitte, Berlin, Germany; Department of Pneumology, Universitätsklinikum Frankfurt, Frankfurt, Germany; Department of Oncology, Hospital Barmherzigen Brüder Trier, Trier, Germany; Department NCT/UCC Early Clinical Trial Unit, Technische Universität Dresden, Dresden, Germany; Department of Oncology, Schwarzwald-Baar Klinikum, Villingen-Schwenningen, Germany; Department of Pneumology, Universitätsklinikum Ulm, Ulm, Germany; Department of Hematology and Oncology, Ortenau Klinikum Lahr, Ortenau, Germany; Department of Pneumology, Universitätsmedizin Greifswald, Greifswald, Germany; Department of Pneumology, Ev. Lungenklinik Berlin, Berlin, Germany; Department of Oncology, Klinikum Darmstadt, Darmstadt, Germany; Department of Oncology Klinikum München Großhadern, München, Germany; Medical Care Centre West Haematology-Oncology, Würselen, Germany; Translational Research Unit, Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany; Institute of Medical Biometry, University of Heidelberg, Heidelberg, Germany; Institute of Pathology, University Hospital Heidelberg, Heidelberg, GermanyShow moreShow less
Source PDF DOI Publisher page
42 days

Pretreatment FDG-PET Biomarkers Predict Regional and Distant Failure but Not Local Recurrence Following Modern Use of Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer

Authors
Dasantha Jayamanne; Joseph Chan; Riche Mohan; Sameer Dave; Sally Ayesa; Geoff Schembri; Venkatesha Venkatesha; Nick Pavlakis; Malinda Itchins; Alex Davis; Ben Harris; Michael Hibbert; Garrick Don; Stephen ClarkeShow moreShow less
Affiliations
Radiation Oncology, Northern Sydney Local Health District Executive, Royal North Shore Hospital, Sydney, New South Wales, Australia; Sydney University Medical Faculty, Sydney, New South Wales, Australia; Nuclear Medicine, Northern Sydney Local Health District Executive, Royal North Shore Hospital, Sydney, New South Wales, Australia; Research Directorate, Northern Sydney Local Health District Executive, Royal North Shore Hospital, Sydney, New South Wales, Australia; Medical Oncology, Northern Sydney Local Health District Executive, Royal North Shore Hospital, Sydney, New South Wales, Australia; Respiratory Medicine, Northern Sydney Local Health District Executive, Royal North Shore Hospital, Sydney, New South Wales, AustraliaShow moreShow less
Source PDF DOI Publisher page
77 days

Stage I Lung Adenocarcinoma in Young Patients (Aged ≤ 50 Years): Beyond Female Nonsmokers

Authors
Hina Bhat; Hely Ollila; Amina Tidjani; Victoria Cranwell; Vincent Galea; Soo-Ryum Yang; Gaetano Rocco; Matthew J. Bott; David R. Jones; Prasad S. AdusumilliShow moreShow less
Affiliations
Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NYShow moreShow less
Source PDF DOI Publisher page
73 days

Using Induction Chemoimmunotherapy as a Bridge to Definitive Local Therapy for Non-Metastatic NSCLC: Real-World Outcomes From a Comprehensive Cancer Center

Authors
Troy J. Kleber; Sage A. Copling; Andrew D. Kim; César P. Márquez; Wenli Dong; Waree Rinsurongkawong; Vadeerat Rinsurongkawong; J. Jack Lee; Yuliya Kitsel; Xiaoyu Han; Sherif M. Ismail; Hui Xu; Ivan Coronado; Zhongxing Liao; Joe Y. Chang; Aileen Chen; Saumil Gandhi; Matthew S. Ning; Quynh-Nhu Nguyen; Michael S. O’Reilly; David Qian; James W. Welsh; Stephen G. Chun; Tina Cascone; Jianjun J. Zhang; Don L. Gibbons; Mehmet Altan; Ara A. Vaporciyan; David C. Rice; Ravi Rajaram; Reza J. Mehran; Mara B. Antonoff; Kyle G. Mitchell; Annikka Weissferdt; John V. Heymach; Jia Wu; Steven H. Lin; Julianna K. BronkShow moreShow less
Affiliations
Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; McGovern Medical School at UTHealth Houston., Houston, TX; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Imaging Physics, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX; Institute for Data Science in Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Thoracic Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Thoracic-Head & Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Thoracic and Cardiovascular Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Anatomical Pathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TXShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does Clinical Lung Cancer take to review a manuscript?

As of 2026-11-14, CrushSCI has 15 complete review records for Clinical Lung Cancer. The fastest paper went from submission to acceptance in 33 days (Rationale and Study Design of the GUIDANCE trial: A Multicenter Phase II Trial of Maintenance Durvalumab and Olaparib After Standard Fist Line Treatment (Carboplatin/Cisplatin, Etoposide, and Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (AIO-TRK-0124/ass), received 2026-06-30, accepted 2026-08-02); the slowest took 211 days. The average is 110.1 days and the median is 83 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.